Skip to content
You are now leaving to visit

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data

Positive interim analysis demonstrated proof-of-biology and proof-of-concept for BIIB067 Biogen plans to advance BIIB067 to a pivotal clinical study Biogen paid Ionis Pharmaceuticals a $35 million one-time upfront payment and may pay potential milestone payments and royalties CAMBRIDGE, Mass.